The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Gilead Sciences has agreed to acquire MYR GmbH, a Bad Homburg, Germany-based biopharmaceutical company focused on developing and commercializing therapeutics for treating chronic hepatitis delta virus (HDV), in a EUR 1.45-billion ($1.75-billion)...
A roundup of news from France (Sanofi), Germany (BioNTech), Japan (Takeda), the UK (AstraZeneca), and the US (Aurobindo).
France
Sanofi, Kiadis Pharma Update on $358-M AcquisitionSanofi and Kiadis Pharma, an Amsterdam-based clinical-stage company...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have received approval for emergency use of their mRNA vaccine candidate, BNT162b2, against SARS-CoV-2, the virus that causes COVID-19, by the UK’s Medicines & Healthcare...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, has filed requests for an emergency use authorization (EUA) from the US Food and Drug Administration (FDA) and conditional approval from...
Eli Lilly and Company has entered into a $812.5-million purchase agreement with the US government for 650,000 additional doses of its neutralizing antibody against COVID-19, bamlanivimab (700 mg). The purchase agreement and doses will be delivered...
Biogen and Sage Therapeutics, a Cambridge, Massachusetts-based pharmaceutical company focused on central nervous system disorders, have entered into a global collaboration and license agreement to develop and commercialize therapies for depression...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from J&J, Takeda, Amgen, UCB, Regeneron, Novavax, Roche, Inovio, and Kaneka.
Manufacturing and supply of COVID-19 vaccines and drugs
Covaxx in $2.8-Bn Worth...
Bayer has completed its acquisition of Asklepios BioPharmaceutical (AskBio), a Research Triangle Park, North Carolina-based clinical-stage gene-therapy company, in a deal worth up to $4 billion ($2 billion upfront and up to $2 billion in milestone...
A roundup of news from Australia (CSL’s Seqirus), China (Pfizer), The Netherlands (Roche), the UK (Eisai, GSK, AstraZeneca), and the US (BMS, Sanofi, Daiichi Sankyo, J&J).
Australia
Seqirus To Invest $584 M in Influenza Vaccine Mfg...
The latest on manufacturing and potential treatments for COVID-19 with news from Moderna, Eli Lilly and Company, AstraZeneca, the World Health Organization, and others.
Manufacturing and supply of COVID-19 vaccines and drugs
Moderna, EU in Supply...
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, reported that they have submitted a request to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) of their mRNA vaccine candidate, BNT162b2, against...
Novartis has formed an exclusive worldwide license and collaboration agreement, in a deal worth up to $1.355 billion ($50 million upfront and $1.305 billion in milestones and other payments), with Mesoblast, a Melbourne, Australia-based developer...
Merck & Co has agreed to acquire OncoImmune, a Rockville, Maryland-based clinical-stage biopharmaceutical company with a drug to treat COVID-19 in Phase III development, in a $475-million deal.
OncoImmune recently announced positive findings...
Eli Lilly and Company and Precision BioSciences, a Durham, North Carolina-based genome-editing company, have formed a research collaboration and exclusive license agreement to develop potential therapies for genetic disorders, in a...
Emer Cooke, formerly Director with the World Health Organization, began her new role as Executive Director of the European Medicines Agency (EMA) last week (November 16, 2020). She succeeds Guido Rasi, who completed his second term as Executive...
